These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 30127915)

  • 21. Evaluation of the ESUR PI-RADS scoring system for multiparametric MRI of the prostate with targeted MR/TRUS fusion-guided biopsy at 3.0 Tesla.
    Roethke MC; Kuru TH; Schultze S; Tichy D; Kopp-Schneider A; Fenchel M; Schlemmer HP; Hadaschik BA
    Eur Radiol; 2014 Feb; 24(2):344-52. PubMed ID: 24196383
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Combining clinical and MRI data to manage PI-RADS 3 lesions and reduce excessive biopsy.
    Yang S; Zhao W; Tan S; Zhang Y; Wei C; Chen T; Shen J
    Transl Androl Urol; 2020 Jun; 9(3):1252-1261. PubMed ID: 32676408
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Multiparametric magnetic resonance imaging - Transrectal ultrasound-guided cognitive fusion biopsy of the prostate: Clinically significant cancer detection rates stratified by the Prostate Imaging and Data Reporting System version 2 assessment category.
    John S; Cooper S; Breau RH; Flood TA; Cagiannos I; Lavallee LT; Morash C; O'sullivan J; Schieda N
    Can Urol Assoc J; 2018 Dec; 12(12):401-406. PubMed ID: 29940139
    [TBL] [Abstract][Full Text] [Related]  

  • 24. PI-RADS Versions 2 and 2.1: Interobserver Agreement and Diagnostic Performance in Peripheral and Transition Zone Lesions Among Six Radiologists.
    Bhayana R; O'Shea A; Anderson MA; Bradley WR; Gottumukkala RV; Mojtahed A; Pierce TT; Harisinghani M
    AJR Am J Roentgenol; 2021 Jul; 217(1):141-151. PubMed ID: 32903060
    [No Abstract]   [Full Text] [Related]  

  • 25. Assessing the validity of Prostate Imaging Reporting and Data System version 2 (PI-RADS v2) scoring system in diagnosis of peripheral zone prostate cancer.
    Dola EF; Nakhla OL; Genidi EA
    Eur J Radiol Open; 2017; 4():19-26. PubMed ID: 28377946
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Diagnostic Performance of PI-RADS v2, Proposed Adjusted PI-RADS v2 and Biparametric Magnetic Resonance Imaging for Prostate Cancer Detection: A Preliminary Study.
    Cai GH; Yang QH; Chen WB; Liu QY; Zeng YR; Zeng YJ
    Curr Oncol; 2021 May; 28(3):1823-1834. PubMed ID: 34065851
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Diagnostic performance of PI-RADS version 2.1 compared to version 2.0 for detection of peripheral and transition zone prostate cancer.
    Rudolph MM; Baur ADJ; Cash H; Haas M; Mahjoub S; Hartenstein A; Hamm CA; Beetz NL; Konietschke F; Hamm B; Asbach P; Penzkofer T
    Sci Rep; 2020 Sep; 10(1):15982. PubMed ID: 32994502
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparison of Prostate Imaging and Reporting Data System V2.0 and V2.1 for Evaluation of Transition Zone Lesions: A 5-Reader 202-Patient Analysis.
    Kim N; Kim S; Prabhu V; Shanbhogue K; Smereka P; Tong A; Anthopolos R; Taneja SS; Rosenkrantz AB
    J Comput Assist Tomogr; 2022 Jul-Aug 01; 46(4):523-529. PubMed ID: 35405714
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison of Multiparametric MRI Scoring Systems and the Impact on Cancer Detection in Patients Undergoing MR US Fusion Guided Prostate Biopsies.
    Rastinehad AR; Waingankar N; Turkbey B; Yaskiv O; Sonstegard AM; Fakhoury M; Olsson CA; Siegel DN; Choyke PL; Ben-Levi E; Villani R
    PLoS One; 2015; 10(11):e0143404. PubMed ID: 26605548
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Targeted MRI/TRUS fusion-guided biopsy in men with previous prostate biopsies using a novel registration software and multiparametric MRI PI-RADS scores: first results.
    Tewes S; Hueper K; Hartung D; Imkamp F; Herrmann TR; Weidemann J; Renckly S; Kuczyk MA; Wacker F; Peters I
    World J Urol; 2015 Nov; 33(11):1707-14. PubMed ID: 25774003
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Structured reporting in radiologic education - Potential of different PI-RADS versions in prostate MRI controlled by in-bore MR-guided biopsies.
    Garmer M; Karpienski J; Groenemeyer DH; Wagener B; Kamper L; Haage P
    Br J Radiol; 2022 Mar; 95(1131):20210458. PubMed ID: 34914538
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparison of diagnostic performance between two prostate imaging reporting and data system versions: A systematic review.
    Li W; Xin C; Zhang L; Dong A; Xu H; Wu Y
    Eur J Radiol; 2019 May; 114():111-119. PubMed ID: 31005160
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Impact of qualitative, semi-quantitative, and quantitative analyses of dynamic contrast-enhanced magnet resonance imaging on prostate cancer detection.
    Ziayee F; Ullrich T; Blondin D; Irmer H; Arsov C; Antoch G; Quentin M; Schimmöller L
    PLoS One; 2021; 16(4):e0249532. PubMed ID: 33819295
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Diffusion weighted image-guided transitional zone scoring in the detection of transitional zone prostate cancer: comparison with current PI-RADS v2.1 scoring.
    Lee MS; Park JH; Kim SY; Kim TM; Oh S; Moon MH
    Abdom Radiol (NY); 2024 Oct; ():. PubMed ID: 39354237
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prospective comparison of a fast 1.5-T biparametric with the 3.0-T multiparametric ESUR magnetic resonance imaging protocol as a triage test for men at risk of prostate cancer.
    Van Nieuwenhove S; Saussez TP; Thiry S; Trefois P; Annet L; Michoux N; Lecouvet F; Tombal B
    BJU Int; 2019 Mar; 123(3):411-420. PubMed ID: 30240059
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Central zone lesions on magnetic resonance imaging: Should we be concerned?
    Tan WP; Mazzone A; Shors S; Antoine N; Ekbal S; Khare N; McKiel C; Pessis D; Deane L
    Urol Oncol; 2017 Jan; 35(1):31.e7-31.e12. PubMed ID: 27692837
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prostate cancer detection on transrectal ultrasonography-guided random biopsy despite negative real-time magnetic resonance imaging/ultrasonography fusion-guided targeted biopsy: reasons for targeted biopsy failure.
    Cash H; Günzel K; Maxeiner A; Stephan C; Fischer T; Durmus T; Miller K; Asbach P; Haas M; Kempkensteffen C
    BJU Int; 2016 Jul; 118(1):35-43. PubMed ID: 26384851
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cutoff Values of Prostate Imaging Reporting and Data System Version 2.1 Score in Men With Prostate-specific Antigen Level 4 to 10 ng/mL: Importance of Lesion Location.
    Chen Y; Ruan M; Zhou B; Hu X; Wang H; Liu H; Liu J; Song G
    Clin Genitourin Cancer; 2021 Aug; 19(4):288-295. PubMed ID: 33632569
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Low PI-RADS assessment category excludes extraprostatic extension (≥pT3a) of prostate cancer: a histology-validated study including 301 operated patients.
    Alessi S; Pricolo P; Summers P; Femia M; Tagliabue E; Renne G; Bianchi R; Musi G; De Cobelli O; Jereczek-Fossa BA; Bellomi M; Petralia G
    Eur Radiol; 2019 Oct; 29(10):5478-5487. PubMed ID: 30887199
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Direct Comparison of PI-RADS Version 2 and 2.1 in Transition Zone Lesions for Detection of Prostate Cancer: Preliminary Experience.
    Byun J; Park KJ; Kim MH; Kim JK
    J Magn Reson Imaging; 2020 Aug; 52(2):577-586. PubMed ID: 32045072
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.